Breast Cancer Risk Perception
Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.
Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.
As there is a plethora of information about breast cancer awareness and early detection, Attai says, many women do not have a good sense of their true risk. A study presented at the 2013 Breast Cancer Symposium showed that in over 9,000 women, 40-45% either underestimated or overestimated their risk by at least 10%.
If a patient is at high risk but believes that she is at lower risk, Attai says, she may be less likely to see the need to take tamoxifen for risk reduction or may not see the need for lifestyle changes. If a patient is at low risk for breast cancer, she may believe she needs prophylactic mastectomies for no good medical reason.
Clinical Pearls
It is important for all of a patient's physicians to give them an idea of what is truly their risk.
- Many women do not have a good sense of their true risk of breast cancer
- In over 9,000 women, 40-45% either underestimated or overestimated their risk by at least 10%
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
